Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shiver away diabetes? new study tests cold therapy for blood sugar control

NCT ID NCT07573917

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether spending time in the cold enough to shiver can improve how the body handles sugar in people with type 2 diabetes. Fifteen adults aged 40-75 with type 2 diabetes will undergo 10 days of cold exposure with shivering. Researchers will measure changes in insulin sensitivity and fat metabolism using glucose clamps and PET scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients are able to provide signed and dated written informed consent prior to any study specific procedures * Women are post-menopausal (defined as at least 1 year post cessation of menses) * Aged ≥ 40 years and ≤ 75 years * Patients should have suitable veins for cannulation or repeated venipuncture * Body mass index (BMI) 25-38 kg/m2 * Stable dietary habits (no weight loss or gain \>5kg in the past 3 months) * Diagnosed with T2D at least 1.5 years before the start of the study * Relatively well-controlled T2D: HbA1c \< 8.5% * Oral glucose-lowering medication: metformin alone or in combination with sulfonylurea agents and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months. In case of GLP-1 agonist medication treatment inclusion will be discussed with the dependent physician. * No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy * No signs of active liver or kidney malfunction Exclusion Criteria: * Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator * Participate in sports of physical activity at a moderate- to high-intensity more than 3 times a week, or as judged by the investigator * Being cold-acclimated, e.g. having taken daily extended cold baths, working in a refrigerated environment, or practicing regular cold-water swimming/ showering within 1 month of starting the study * Unstable body weight (weight gain or loss \> 5 kg in the last three months) * Alcohol consumption of \>2 servings per day for man and \>1 servings per day for women * Smoking * Being insulin-dependent and/or using SGLT2 inhibitor medications * Patients with congestive heart failure and and/or severe renal and or liver insufficiency * Men: Hb \<8.4 mmol/L, Women: Hb \<7.8 mmol/l * A medical doctor will judge participation eligibility based on the medical history questionnaire, medication use and fasting blood parameters. If the medical doctor advises that a patient cannot participate, the patient will be excluded from enrolment. * Being pregnant * Having participated in another study involving PET/CT scanning in the past 1 year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre de recherche du CHUS

    RECRUITING

    Sherbrooke, Quebec, J1H 5N4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.